OKYO Pharma director buys 5,000 shares at $1.477

OKYO Pharma Ltd director John P. Brancaccio reported an open-market purchase of 5,000 shares of common stock on July 21, 2026 at $1.477 per share.

Accepted by SEC EDGAR 08/07/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd director John P. Brancaccio reported an open-market purchase of 5,000 shares of common stock on July 21, 2026 at $1.477 per share. Following this trade, he directly owns 35,201 shares.

The amended insider report corrects the transaction code for this purchase and indicates the trade was not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider BRANCACCIO JOHN P

Role Director

Bought 5,000 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	5,000	$1.477	$7K

Holdings After Transaction: COMMON STOCK — 35,201 shares (Direct)

Key Figures

Shares purchased: 5,000 shares Purchase price: $1.477 per share Shares owned after transaction: 35,201 shares +1 more

4 metrics

Shares purchased 5,000 shares Common stock bought on July 21, 2026

Purchase price $1.477 per share Open-market transaction price

Shares owned after transaction 35,201 shares Direct ownership following the reported purchase

Net buy shares 5,000 shares Net buy-sell volume reported in this insider transaction

Key Terms

Form 4/A, open market purchase, non-derivative

3 terms

Form 4/A regulatory

"This Form 4/A amends the Form 4 filed on July 23, 2026"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

open market purchase financial

"correct the transaction code associated with this open market purchase"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

non-derivative financial

""transaction_type": "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider purchase did OKYO (OKYO) director John P. Brancaccio report?

He reported an open-market purchase of 5,000 OKYO Pharma common shares on July 21, 2026 at $1.477 per share. After this transaction, his directly held position increased to 35,201 shares, based on the amended insider ownership disclosure.

When did the OKYO (OKYO) insider transaction occur and at what price?

The reported insider transaction occurred on July 21, 2026, when John P. Brancaccio bought 5,000 OKYO Pharma common shares. The shares were acquired in the open market at a price of $1.477 per share.

How many OKYO (OKYO) shares does John P. Brancaccio own after this trade?

After the reported purchase, John P. Brancaccio directly owns 35,201 OKYO Pharma common shares. This post-transaction holding reflects his direct ownership position following the acquisition of 5,000 shares in the open-market transaction on July 21, 2026.

Why was an amended insider report filed for OKYO Pharma Ltd (OKYO)?

An amended insider report was filed solely to correct the transaction code associated with the reported open-market purchase. The amendment states that no other previously reported transactions are affected, and the economic details of the 5,000-share purchase remain unchanged.

Was the OKYO (OKYO) insider purchase made under a Rule 10b5-1 trading plan?

The transaction was not reported as made under a Rule 10b5-1 trading plan. The Rule 10b5-1 checkbox was left unchecked, indicating the open-market purchase of 5,000 shares was not executed pursuant to a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRANCACCIO JOHN P

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/23/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/21/2026		P		5,000	A	$1.477	35,201	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4/A amends the Form 4 filed on July 23, 2026 solely to correct the transaction code associated with this open market purchase. No other reported transactions are affected by this amendment.

	/s/ John Brancaccio	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)